1. Home
  2. SBR vs MGTX Comparison

SBR vs MGTX Comparison

Compare SBR & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sabine Royalty Trust

SBR

Sabine Royalty Trust

HOLD

Current Price

$72.50

Market Cap

1.0B

Sector

Energy

ML Signal

HOLD

Logo MeiraGTx Holdings plc

MGTX

MeiraGTx Holdings plc

HOLD

Current Price

$13.39

Market Cap

909.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBR
MGTX
Founded
1982
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
909.1M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
SBR
MGTX
Price
$72.50
$13.39
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$24.57
AVG Volume (30 Days)
27.3K
1.2M
Earning Date
05-14-2026
05-12-2026
Dividend Yield
6.41%
N/A
EPS Growth
N/A
33.02
EPS
N/A
N/A
Revenue
N/A
$81,391,000.00
Revenue This Year
N/A
$141.38
Revenue Next Year
N/A
N/A
P/E Ratio
$12.77
N/A
Revenue Growth
N/A
144.57
52 Week Low
$65.15
$6.62
52 Week High
$84.39
$15.35

Technical Indicators

Market Signals
Indicator
SBR
MGTX
Relative Strength Index (RSI) 44.67 62.91
Support Level $72.41 $7.21
Resistance Level $73.00 N/A
Average True Range (ATR) 1.53 0.95
MACD 0.16 0.14
Stochastic Oscillator 33.99 53.96

Price Performance

Historical Comparison
SBR
MGTX

About SBR Sabine Royalty Trust

Sabine Royalty Trust formed to receive Sabine Corporation's royalty and mineral interests, including landowner's royalties, overriding royalty interests, minerals production payments and any other similar, non-participatory interests, in certain Royalty Properties. The trusts producing and proved undeveloped oil and gas royalty properties are located in Florida, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.

About MGTX MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.

Share on Social Networks: